- earnings
Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive
MELBOURNE, Australia, Feb. 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the financial year ended 31 December 2022. All figures are in AU$ unless otherwise stated. 2022 HIGHLIGHTS Total Group revenue $160.1M (2021: $7.6M) commercial launch of Illuccix® drives 20x increase in revenueHighly positive top-line data from Phase III ZIRCON trial of investigational...
Read more